✦ LIBER ✦

Three-year results of a randomized controlled clinical trial of the posterior composite QuiXfil in class I and II cavities

✍ Scribed by Juergen Manhart; Hong-Yan Chen; Reinhard Hickel

Publisher: Springer
Year: 2008
Tongue: English
Weight: 132 KB
Volume: 13
Category: Article
ISSN: 1432-6981
DOI: 10.1007/s00784-008-0233-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The vitamin D analogue 2MD increases bon

The vitamin D analogue 2MD increases bone turnover but not BMD in postmenopausal women with osteopenia: Results of a 1-year phase 2 double-blind, placebo-controlled, randomized clinical trial

✍ Hector F DeLuca; Wendy Bedale; Neil Binkley; J Chris Gallagher; Michael Bolognes 📂 Article 📅 2011 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 215 KB 👁 1 views

## Abstract Most osteoporosis drugs act by inhibiting bone resorption. A need exists for osteoporosis therapies that stimulate new bone formation. 2‐Methylene‐19‐nor‐(20__S__)‐1α,25‐dihydroxyvitamin D~3~ (2MD) is a vitamin D analogue that potently stimulates bone formation activity in vitro and in

Recombinant human anti–transforming grow

Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192

✍ Christopher P. Denton; Peter A. Merkel; Daniel E. Furst; Dinesh Khanna; Paul Eme 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 1 views

## Abstract ## Objective To evaluate CAT‐192, a recombinant human antibody that neutralizes transforming growth factor β1 (TGFβ1), in the treatment of early‐stage diffuse cutaneous systemic sclerosis (dcSSc). ## Methods Patients with SSc duration of <18 months were randomly assigned to the place